BioLizard and Tercen announce Partnership

BioLizard and Tercen announce a partnership to combine BioLizard’s advanced bioinformatics and AI/ML services with Tercen’s intuitive low-code analytics platform, enabling faster, more comprehensive biomedical data analysis and visualization for life sciences researchers worldwide.

Ghent, March 31st, 2023.

Tercen and BioLizard today announced their partnership.

BioLizard is an agile bioinformatics and AI/ML company globally servicing clients in the life sciences, biotechnology, and pharmaceutical industries.

Tercen is an interactive bioinformatics platform that facilitates visual-based analysis of large biomedical datasets and easy collaborations.

The complementarity of Tercen’s analytics platform and BioLizard’s tailored advanced analytics services will benefit both companies’ services.

Originating from Ghent (Belgium) and with offices in the Netherlands and the US, BioLizard has a strong track record in providing cutting-edge bioinformatics, data science, software development, and data management solutions to manage, process, and analyze even the most complex scientific data.

These in-depth capabilities of BioLizard and the easy-to-use platform of Tercen are highly complementary and result in faster and more complete analytics services.

Tercen, a bioinformatics software company with offices in Waterford (Ireland), has developed a low-code platform for intuitive bioinformatics analysis and visualization of biomedical data.

The platform allows researchers to perform bioinformatic analysis and data visualization in an intuitive way.

Both companies are convinced the complementarity between them will benefit their respective customers. Tercen’s platform complements BioLizard’s in-depth analytics services and allows researchers to perform hands-on analysis themselves.

BioLizard’s expertise in advanced analytics, data mining, and data visualisation will benefit Tercen users that require more in-depth analysis of highly complex datasets or biological questions.

How spatial biology improves clinical trial success in oncology

How spatial biology improves clinical trial success in oncology

In oncology, the drug development path is unique: Phase 0 and Phase I trials are typically conducted in patients rather than healthy volunteers, allowing for early assessment of efficacy and patient selection alongside safety. Yet, even with this early clinical insight, many cancer drugs show promise in the lab but fail to transition effectively into the clinic. This often happens because, while we verify that a drug’s target is present, we frequently overlook its context, specifically its location, the surrounding microenvironment, and its interaction with neighboring cells. By revisiting real-world examples of discontinued trials, this post explains why understanding the “where” is just as critical as the “what”, and how spatial biology is positioning itself as a valuable avenue for validating clinical potential.

Why bioinformatics workflows require experienced software engineers

Bioinformatics pipelines break for the smallest reasons: package updates, shifting dependencies, or “it only works on my machine.” This post explains why experienced software engineers and DevOps practices (Git, CI/CD, IaC) are essential to keep workflows reproducible, stable, and scalable.